Purpose: Understanding the mechanism of radioresistance could help develop strategies to improve therapeutic response of patients with PDAC. The SMAD4 gene is frequently mutated in pancreatic cancer. In this study, we investigated the role of SMAD4 deficiency in pancreatic cancer cells' response to radiotherapy.

Experimental Design: We downregulated SMAD4 expression with SMAD4 siRNA or SMAD4 shRNA and overexpressed SMAD4 in SMAD4 mutant pancreatic cancer cells followed by clonogenic survival assay to evaluate their effects on cell radioresistance. To study the mechanism of radioresistance, the effects of SMAD4 loss on reactive oxygen species (ROS) and autophagy were determined by flow cytometry and immunoblot analysis, respectively. Furthermore, we measured radioresistance by clonogenic survival assay after treatment with autophagy inhibitor (Chloroquine) and ROS inhibitor (N-acetyl-l-cysteine) in SMAD4-depleted pancreatic cancer cells. Finally, the effects of SMAD4 on radioresistance were also confirmed in an orthotopic tumor model derived from SMAD4-depleted Panc-1 cells.

Results:SMAD4-depleted pancreatic cancer cells were more resistant to radiotherapy based on clonogenic survival assay. Overexpression of wild-type SMAD4 in SMAD4-mutant cells rescued their radiosensitivity. Radioresistance mediated by SMAD4 depletion was associated with persistently higher levels of ROS and radiation-induced autophagy. Finally, SMAD4 depletion induced in vivo radioresistance in Panc-1-derived orthotopic tumor model (P = 0.038). More interestingly, we observed that the protein level of SMAD4 is inversely correlated with autophagy in orthotopic tumor tissue samples.

Conclusions: Our results demonstrate that defective SMAD4 is responsible for radioresistance in pancreatic cancer through induction of ROS and increased level of radiation-induced autophagy. Clin Cancer Res; 24(13); 3176–85. ©2018 AACR.

Translational Relevance

Adjuvant radiotherapy is often given following surgery for pancreatic ductal adenocarcinoma (PDAC). However there is still controversy about whether the patients benefit from radiotherapy. In the United States, chemoradiotherapy is accepted as appropriate adjuvant therapy of PDAC, but standard adjuvant treatment in Europe is chemotherapy alone. There might be a certain group of PDAC patients who could get some measurable benefit from radiotherapy, however that group is not well defined and further evaluation of biomarkers might help to more precisely determine that group. Gene mutations could affect therapy responses of cancer cells, and SMAD4 is mutated in 55% PDAC patients. This study documents that SMAD4 depletion increases radioresistance of pancreatic cancer cells both in vitro and in vivo. SMAD4 depletion induces high levels of reactive oxygen species (ROS) and autophagy. Pretreatment with N-acetyl-l-cysteine (NAC), a ROS inhibitor, or chloroquine (CQ), an autophagy inhibitor, could resensitize SMAD4-depleted cells to IR. Future studies are needed to investigate the relationship of SMAD4 status and survival advantages of chemoradiotherapy in patients with PDAC, which would be helpful to guide the administration of targeted therapies in the adjuvant setting based on SMAD4 status.

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease of the exocrine pancreas, and is the fourth most common cause of cancer deaths worldwide, leading to estimated 227,000 deaths annually (1, 2). Despite advances in conventional therapies (surgical, chemotherapy, and radiotherapy), little improvement has been observed in the survival rate over the past 30 years (3). The median survival of patients with PDAC is less than 6 months, and the 5-year survival rate is less than 5% (1–3). Since early-stage pancreatic cancer is usually clinically silent, most patients have already developed locally advanced or metastatic disease at diagnosis, and only 10% to 15% of the patients are eligible for surgical resection (4, 5). Most pancreatic cancer patients are treated with chemotherapy in the United States, either alone or in combination with radiotherapy (6–8), whereas chemotherapy is frequently used alone in patients in Europe, based on the European organization for Research and Treatment of Cancer (EORTC) trail (9). However, the U.S. study was criticized for poor patient accrual, early termination, small patient number and suboptimal radiotherapy dose. At the same time, there are some defects in EORTC trial design, including the mixing up of pancreas and peri-ampullary cancers, underpowered analysis for survival benefit, and use of antiquated radiotherapy and chemotherapy techniques. A growing body of evidence showed no survival benefit for adjuvant chemoradiotherapy but revealed a potential benefit for adjuvant chemotherapy (10–13). However, the true benefit of the addition of radiotherapy is still unknown (14). The underlying reason for the striking difference in guidelines of PDAC treatment between these different regions is still unclear. Because many gene mutations affect cell growth and drug responses of cancer cells, we suspect that the difference in the mutational status of some key genes in the pancreatic cancer patients may contribute to resistance to radiotherapy.

Mutations in multiple genes such as SMAD4, KRAS, TP53, and CDKN2A/INK4A (15, 16) have been demonstrated to be important in PDAC progression. Among these, the SMAD4 status is considered to be an important molecular feature which distinguishes two major classes of PDAC. The tumor suppressor gene SMAD4 encoding a common intracellular mediator of the TGFβ superfamily is mutated or deleted in 55% pancreatic cancers (16, 17). This gene is also inactivated at varying frequency in breast, colorectal, and gastric cancer (18, 19). Loss of SMAD4 promotes pancreatic tumor progression and increases metastasis (20, 21). SMAD4 is reported as a negative prognostic factor for overall survival (17, 22–24). Growing evidence showed that the loss of SMAD4 induces resistance to chemotherapy in colorectal, breast, head, and neck cancers (25–27). However, the role of SMAD4 in radioresistance of pancreatic cancer and the underlying molecular mechanism have not been fully elucidated.

In this study, we showed that SMAD4 depletion renders pancreatic cancer cells resistant to ionizing radiation (IR) both in vitro and in vivo. Mechanistically, SMAD4 depletion induces high levels of autophagy and ROS, which appear to contribute to such radioresistance.

Cell lines and culture

The human pancreatic cancer cell lines Panc-1 and MIA PaCa-2 were purchased from the ATCC. Cells were maintained in DMEM medium (GIBCO) supplemented with 10% or 20% FBS and 100 U/mL penicillin (GIBCO). Panc-1 cells transfected with shRNA (Panc-1-shControl and Panc-1-shSMAD4) were maintained in DMEM medium (GIBCO) supplemented with 10% FBS, 100 U/mL penicillin, and 1 μg/mL puromycin (Sigma). All cell lines were cultured in a 37°C incubator with 95% air and 5% CO2. Each cell line was authenticated and regularly tested for mycoplasma contamination.

Reagents and antibodies

Lipofectamine 2000 (Invitrogen) was applied to transfect PcDNA3-Flag-SMAD4 plasmid (Addgene plasmid #80888) into cells by following manufacturers' instruction. N-acetyl-L-cysteine (NAC) and chloroquine (CQ) were purchased from Sigma-Aldrich, and were reconstituted in DMSO and PBS at 100 mmol/L, respectively. Antibodies against SMAD4, Rad51, BRCA-1, LC3, FLAG, and γ-H2AX were purchased from Cell Signaling Technology Inc. A monoclonal anti-β-actin antibody was obtained from Sigma.

Measurement of ROS

Cells were seeded for 24 hours at a density of 3 × 105 cells/mL prior to IR treatment. The level of intracellular ROS was measured using the fluorescent probe 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) following manufacturer's instruction (Life Technologies). In brief, cells were incubated with 10 μmol/L CM-H2DCFDA for 30 minutes at 37°C in the dark and then washed in serum-free minimum essential medium without phenol red. The cells were then analyzed in a FACSCanto apparatus (BD Biosciences).

siRNA transfection

Cells were grown to confluence in 6-cm tissue culture plates, and transfected with one of the four SMAD4-specific siRNA oligos at 50 nmol/L final concentration (si-SMAD4-a: 5′-AGAUGAAUUGGAUUCUUUAdTdT-3′; si-SMAD4-b: 5′-GUGUGCAGUUGGAAUGUAAdTdT-3′; si-SMAD4-c: 5′-GUACUUCAUACCAUGCCGAdTdT-3′; si-SMAD4-d: 5′-CAUCCUAGUAAAUGUGUUAdTdT-3′) using INTERFERin as the transfection reagent according to the manufacturer's instruction. A scrambled siRNA (siScr: 5′-ACGCGUAACGCGGGAAUUUdTdT-3′) was applied as a negative control. Cells were harvested 72 hours later for gene expression analysis by Western blot analysis.

Retroviral shRNA production

Retroviral vectors carrying a human SMAD4-specific shRNA (target sequence 1: 5′-GGTGTGCAGTTGGAATGTA-3′ for clone #35 and #46. Target sequence 2: 5′-GATTAACACTGCAGAGTAA-3′ for supplementary figures) or a scrambled nontargeting control (sequence: 5′-AAAATGCAGTTGGAATGTA-3) were purchased from Addgene. The shSMAD4 and shControl recombinant viruses were generated by transient transfection with packaging plasmids pMLg/pRRE, pRSV.rev, and pHCMV-G into 293T cells (28). Virus-containing supernatant was collected 72 hours later, and applied to transfect Panc-1 cells, and then selected three individual clones as Panc-1-shSMAD4 #35 and #46 (for target sequence 1) and #2 (for target sequence 2).

In vitro and in vivo IR

For in vitro studies, cells were irradiated at various doses using an XRAD 320 X-ray irradiator (Precision X-Ray, Inc.) at a dose rate of 75 cGy/min. For in vivo IR, mice were anesthetized with ketamine/xylazine (100 mg/kg + 10 mg/kg) and placed in well-ventilated custom jigs (Precision X-Ray), allowing for local delivery of radiation using an XRad 320 X-ray irradiator (Precision X-Ray, Inc.) at a dose rate of 289.8 cGy/min.

Clonogenic assay to measure cell survival

Cell survival was determined using a standard clonogenic assay. Cells with or without SMAD4 knockdown were trypsinized to generate a single-cell suspension and seeded into six-well plates in triplicate. After incubation for 16 hours, 800 cells were treated with IR (0–6 Gy). After 7 to 10 incubation, the colonies were fixed with 4% paraformaldehyde and then stained with 0.5% crystal violet. After counting the number of colonies (containing more than 50 cells), the surviving fraction was calculated.

Western blot analysis

Cells were rinsed twice with PBS and lysed for 2 h with RIPA Lysis buffer (Thermo Scientific) supplemented with a protease inhibitor and a protease inhibitor cocktail. Cell debris was removed by centrifugation at 12,000 rpm for 10 minutes at 4°C. Protein concentration in the supernatant was determined with the BCA Protein Assay Kit (Pierce). The protein samples were separated by electrophoresis using a 4% to 20% Mini-PROTEAN Tetra Cell polyacrylamide gel (Bio-Rad) and then transferred to polyvinylidene fluoride membranes (Bio-Rad). The membrane was blocked with 5% skim milk, and incubated with the indicated primary antibodies, followed by incubation with horseradish peroxidase-labeled secondary antibodies. Antibody-bound proteins were detected using the Enhanced Chemiluminescence (ECL) reagent (GenDEPOT) according to the manufacturer's instructions. The protein levels were quantified using the ImageJ software (NIH) and then normalized by the expression levels in control cells for each group.

Confocal microscopy analysis

Cells were seeded onto four-well LabTek II chamber slides (NUNC) for 24 hours, and then treated with IR at 2, 4 or 6 Gy. After incubation for 2 hours, cells were fixed with 4% paraformaldehyde for 10 minutes, washed three times with PBS and blocked with 3% BSA and 0.1% Triton-X100 in PBS for 30 minutes at room temperature. After removing the blocking buffer, cells were incubated with the primary antibodies (rabbit γ-H2AX antibody, LC3 antibody and mouse SMAD4 antibody) overnight at 4°C. After being washed three times with PBS, cells were incubated with Alexa Fluor 488-conjugated anti-rabbit IgG and Alexa Fluor 594-conjugated anti-mouse IgG secondary antibodies (Invitrogen) for 2 hours in the dark. The cells were then washed and mounted with mounting medium containing DAPI (VECTOR Laboratories, Burlingame, CA, USA). Finally, a Nikon A1 confocal microscope was applied to examine and quantitate γ-H2AX, LC3, and SMAD4 signals. At least 300 nuclei were evaluated for each data point.

In vivo studies

All mouse studies were performed in compliance with the guidelines of the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals following protocols approved by the Institutional Animal Care and Use Committee (IACUC). Six-week-old athymic nude mice were purchased from Charles River Laboratories (Boston, MA). Mice (8 per group) were injected with 2 × 106 Panc-1-shControl or Panc-1-shSMAD4 cells suspended in 100 μL medium with 5% Matrigel directly into the pancreas for orthotopic tumor development. Three weeks after inoculation, the mice received 4 Gy radiation for three times with 2-day intervals between irradiations. The mice were sacrificed at 3 weeks after the last treatment, and the tumors were removed and weighed.

IHC staining of tissue samples

IHC staining was performed as previously described (29). Briefly, tumor sections were deparaffinized, rehydrated, and treated with 10 mmol/L citrate buffer (pH 6.0) at 95°C to retrieve antigens. After quenching endogenous peroxidase activity with H2O2 and blocking with 10% horse serum, the sections were incubated sequentially with the primary antibodies mouse anti-SMAD4 (1:100; Cell Signaling Technology Inc.), rabbit anti-LC3 (1:100; Cell Signaling Technology Inc.), rabbit anti-γ-H2AX (1:100; Cell Signaling Technology Inc.), biotinylated secondary antibodies, and the Avidin-Biotin Complexes (ABC) reagent (Gene Tech). The immunostaining was visualized with 3.3-diaminobenzidine (Gene Tech). The sections were then counterstained with hematoxylin. Negative controls were performed in each case by replacing the primary antibody with PBS.

Statistical analysis

All experiments were performed in triplicate. The data were expressed as means ± SD. Statistical analyses were performed using Student t test and ANOVA. Differences across groups selected to be compared were detected via repeated measures ANOVA. Values of P < 0.05 were considered statistical significant, and all the statistical test were two sides. All statistical analyses were conducted in R program (R core team, version 3.4.2).

SMAD4 knockdown in pancreatic cancer cells results in IR resistance

In order to examine whether SMAD4 was involved in response to IR, we knocked down SMAD4 gene expression in Panc-1 cells with retroviral shRNA constructs (sh-SMAD4 #35 and sh-SMAD4 #46) or siRNA oligos (si-SMAD4-1 and si-SMAD4-2) targeting the SMAD4 gene. To exclude the off-target effect of shRNA, we also established cell lines stably expressing another shRNA construct which targeted different sites in SMAD4. Western blot analysis showed that SMAD4 was depleted by siRNA or shRNA (Fig. 1A and B; Supplementary Fig. S1). The same siRNA oligos were effective in suppressing SMAD4 expression in MIA PaCa-2 cells (Fig. 1C). The cancer cells were treated with various doses of IR, and then seeded on cell culture plates for colony formation. Interestingly, Panc-1 cells infected with the SMAD4 gene-specific shRNA retrovirus were more resistant to IR than both the untreated cells and those treated with retrovirus carrying a control scramble shRNA (Fig. 1D). Similar results were obtained when Pan-1 cells treated with siRNA oligos (Fig. 1E). Consistent with Panc-1 cells, MIA-PaCa-2 cells treated with SMAD4 siRNA oligos were more resistant to IR than those treated with the control siRNA oligos (Fig. 1F). We also found that SMAD4 wild-type (WT) pancreatic cancer cell lines (Panc-1, MIA PaCa-2) were more sensitive to IR than SMAD4 mutated cell lines (Bxpc-3, Capan-1; Fig. 1G). Furthermore, we found that the Bxpc-3 cells transfected with Flag-SMAD4 plasmid were more sensitive to IR than control cells with empty vector (Fig. 1H). These results indicate that suppression of SMAD4 expression increases radioresistance in pancreatic cancer cells.

Figure 1.

SMAD4 knockdown resulted in irradiation resistance in PDAC cells. A–C, Panc-1 cells were transfected with a control shRNA retroviral vector or two independent shRNA retroviral vector against SMAD4 (A), Panc-1 cells were transfected with scrambled siRNA or four SMAD4-specific siRNA for 72 hours (B), Panc-1, MIA PaCa-2 cells were transfected with scrambled siRNA or pool of SMAD4-specific siRNA for 72 hours (C), and total cell lysates were harvested followed by immunoblotting with the indicated antibodies. D–F, Panc-1 cells were transfected with a control shRNA retroviral vector or two independent shRNA retroviral vector targeting SMAD4 (D) or pool of SMAD4-specific siRNA (E), MIA PaCa-2 cells were transfected with scrambled siRNA or SMAD4-specific siRNA pool (F), and then treated with indicated doses of IR. Colony formation assays were conducted and more than 50 cells were counted. G, Colony formation assays were conducted in two SMAD4 mutated cell lines (Bxpc-3, Capan-1) and two SMAD4 WT cell lines (Panc-1, MIA PaCa-2). The differences between SMAD4 WT and mutated cells selected to be compared were detected using repeated measures ANOVA. *, P < 0.05. H, Bxpc-3 cells were transfected with Flag-SMAD4 plasmid or empty vector, followed by colony formation assays. Shown are the averages of triplicate samples. Standard errors are shown by error bars. The differences in the two groups selected to be compared were detected using repeated measures ANOVA. *, P < 0.05 (si-SMAD4-1=si-SMAD4-a+si-SMAD4-b; si-SMAD4-2=si-SMAD4-c+si-SMAD4-d).

Figure 1.

SMAD4 knockdown resulted in irradiation resistance in PDAC cells. A–C, Panc-1 cells were transfected with a control shRNA retroviral vector or two independent shRNA retroviral vector against SMAD4 (A), Panc-1 cells were transfected with scrambled siRNA or four SMAD4-specific siRNA for 72 hours (B), Panc-1, MIA PaCa-2 cells were transfected with scrambled siRNA or pool of SMAD4-specific siRNA for 72 hours (C), and total cell lysates were harvested followed by immunoblotting with the indicated antibodies. D–F, Panc-1 cells were transfected with a control shRNA retroviral vector or two independent shRNA retroviral vector targeting SMAD4 (D) or pool of SMAD4-specific siRNA (E), MIA PaCa-2 cells were transfected with scrambled siRNA or SMAD4-specific siRNA pool (F), and then treated with indicated doses of IR. Colony formation assays were conducted and more than 50 cells were counted. G, Colony formation assays were conducted in two SMAD4 mutated cell lines (Bxpc-3, Capan-1) and two SMAD4 WT cell lines (Panc-1, MIA PaCa-2). The differences between SMAD4 WT and mutated cells selected to be compared were detected using repeated measures ANOVA. *, P < 0.05. H, Bxpc-3 cells were transfected with Flag-SMAD4 plasmid or empty vector, followed by colony formation assays. Shown are the averages of triplicate samples. Standard errors are shown by error bars. The differences in the two groups selected to be compared were detected using repeated measures ANOVA. *, P < 0.05 (si-SMAD4-1=si-SMAD4-a+si-SMAD4-b; si-SMAD4-2=si-SMAD4-c+si-SMAD4-d).

Close modal

SMAD4 depletion results in DNA damage and genomic instability

Radiation kills cancer cells by inducing DNA damage which triggers DNA damage response (DDR), including genomic instability. To investigate whether SMAD4 loss affects genomic stability, we examined several DDR endpoints. Knockdown of SMAD4 expression activated phosphorylation of the H2AX histone (γ-H2AX), a molecular marker for DNA double-strand breaks (DSB; ref. 30), in Panc-1 cells without IR (Fig. 2A). After IR treatment, the γ-H2AX level increased in both control and SMAD4 depleted cells (Fig. 2A; Supplementary Fig. S2). Interestingly, the levels of Brca1 and Rad51, two key proteins involved in DNA DSB repair, were reduced in cells with suppressed SMAD4 expression (Fig. 2A; Supplementary Fig. S2). Immunostaining revealed a similar pattern of γ-H2AX levels in Panc-1 cells (Fig. 2B and C). There was a larger number of γ-H2AX foci in Panc-1 cells treated with si-SMAD4 before IR treatment, and massive staining of γ-H2AX foci were readily visible within 2 hours of IR in the nuclei of Panc-1 cells treated with either the control siRNA or SMAD4 siRNA (Fig. 2B and C). These results indicate that the SMAD4 protein is required for maintaining a proper DDR machinery in cancer cells.

Figure 2.

SMAD4 depletion impaired DNA DSB signaling in Panc-1 cells in response to ionizing radiation. A, Panc-1 cells were transfected with scrambled siRNA, or four independent SMAD4-specific siRNAs for 72 hours, and then total cell lysates were harvested followed by immunoblotting with the indicated antibodies. B and C, Panc-1 cells were transfected with scrambled siRNA or pool of SMAD4-specific siRNAs and then exposed to IR (6 Gy). Laser confocal microscopy images of pancreatic cancer cell lines labeled with fluorescent antibodies to γ-H2AX (red channel), SMAD4 (green channel), and DAPI (blue channel) at 2 hours post-irradiation or mock treatment. Focal γ-H2AX staining signals were quantified in cells. C, The typical staining of γ-H2AX in Panc-1 cells before and after the treatment with irradiation. The average data point was calculated from three independent experiments. At least 1,000 cells were counted for each cell line. The differences in those two groups were detected using t test. **, P < 0.01.

Figure 2.

SMAD4 depletion impaired DNA DSB signaling in Panc-1 cells in response to ionizing radiation. A, Panc-1 cells were transfected with scrambled siRNA, or four independent SMAD4-specific siRNAs for 72 hours, and then total cell lysates were harvested followed by immunoblotting with the indicated antibodies. B and C, Panc-1 cells were transfected with scrambled siRNA or pool of SMAD4-specific siRNAs and then exposed to IR (6 Gy). Laser confocal microscopy images of pancreatic cancer cell lines labeled with fluorescent antibodies to γ-H2AX (red channel), SMAD4 (green channel), and DAPI (blue channel) at 2 hours post-irradiation or mock treatment. Focal γ-H2AX staining signals were quantified in cells. C, The typical staining of γ-H2AX in Panc-1 cells before and after the treatment with irradiation. The average data point was calculated from three independent experiments. At least 1,000 cells were counted for each cell line. The differences in those two groups were detected using t test. **, P < 0.01.

Close modal

Pancreatic cancer cells with suppressed SMAD4 expression exhibits increased level of autophagy

It has been well documented that autophagy occurs in response to IR, which rescues cells from IR-induced cellular damage, thereby contributing to radioresistance (31–33). Inhibition of autophagy has been shown to sensitize tumor cells to the cytotoxic effects of both chemotherapy and radiotherapy (34, 35). In order to determine whether autophagy played a role in SMAD4-dependent resistance to IR, we knocked down SMAD4 expression in Panc-1 and MIA Paca-2 cells, and measured cellular levels of the autophagy marker protein LC3-II, a lipidated LC3 protein that is associated with autophagosomes (36). Western blot analysis revealed that knockdown of SMAD4 promoted the conversion of LC3-I to LC3-II in Panc-1 (1.45-fold increase) and MIA PaCa-2 (2.15-fold increase) cells (Fig. 3A–C). Upon IR (6 Gy) treatment, LC3-II levels increased steadily in a time-dependent manner in both control cells and SMAD4-depleted cells. The peak reached at the 24-hour time point in both cell lines. However, LC3-II increase was more profound in cells with suppressed SMAD4 expression compared with that in control cells. We also observed similar results in the Panc-1 cells stable expressing SMAD4 shRNA (Supplementary Fig. S2A). During authophagy, autophagic flux could be easily visualized by fluorescence microscopy using LC3-II antibody, which is tightly bound to the membrane of autophagosome. Immunofluorescent imaging analysis (Fig. 3D and E; Supplementary Fig. S2B) showed that, in SMAD4-depleted cells, LC3 signals shifted from a diffuse cytoplasmic pattern to a punctate membrane pattern. In addition, SMAD4-depleted cells displayed a higher level of membrane LC3 signal, indicating autophagosome formation (Fig. 3D and E; Supplementary Fig. S2B). Collectively, our results suggest that radioresistance mediated by SMAD4 depletion is accompanied by an increase in autophagic flux in pancreatic cancer cells.

Figure 3.

SMAD4 depletion induced high level of autophagy in response to ionizing radiation. A–C, Panc-1 and MIA PaCa-2 were transfected with scrambled siRNA or SMAD4-specific siRNA for 48 hours and then were treated with or without IR (6 Gy). Cell lysates were harvested at the indicated time points after IR. A, Immunoblot of LC3 isoforms were measured using antibody against LC3. Quantification of the LC3-II/LC3-I ratio in Panc-1 cells (B) and MIA PaCa-2 cells (C). The protein level of the β-actin was used as the internal standard. Shown are the averages of triplicate experiments. D, Representative confocal images of endogenous LC3 staining in Panc-1 transfected with scramble or SMAD4-specific siRNA for 48 hours, and treated with or without IR (6 Gy). Cells were stained with antibody to LC3 (red) and DAPI (blue). Scale bars, 10 μm. E, Quantification of LC3 puncta in Panc-1 cell lines.

Figure 3.

SMAD4 depletion induced high level of autophagy in response to ionizing radiation. A–C, Panc-1 and MIA PaCa-2 were transfected with scrambled siRNA or SMAD4-specific siRNA for 48 hours and then were treated with or without IR (6 Gy). Cell lysates were harvested at the indicated time points after IR. A, Immunoblot of LC3 isoforms were measured using antibody against LC3. Quantification of the LC3-II/LC3-I ratio in Panc-1 cells (B) and MIA PaCa-2 cells (C). The protein level of the β-actin was used as the internal standard. Shown are the averages of triplicate experiments. D, Representative confocal images of endogenous LC3 staining in Panc-1 transfected with scramble or SMAD4-specific siRNA for 48 hours, and treated with or without IR (6 Gy). Cells were stained with antibody to LC3 (red) and DAPI (blue). Scale bars, 10 μm. E, Quantification of LC3 puncta in Panc-1 cell lines.

Close modal

SMAD4 depletion causes persistent ROS increase in pancreatic cancer cells after irradiation exposure

It has been previously reported that autophagy occurs in response to stress, such as ROS (37, 38) and nutrient starvation (39). IR induce intracellular ROS production, and ROS accumulation is necessary for the initiation of autophagy (40–43). We next examined ROS levels in SMAD4-depleted pancreatic cancer cells based on CM-H2DCFDA fluorescence staining (Fig. 4; Supplementary Fig. S3). ROS levels were increased within 2 to 6 hours after IR treatment in Panc-1 and MIA PaCa-2 cell lines (Fig. 4C and D). The basal levels of ROS were elevated in both cell lines with SMAD4 depletion, and radiation-induced ROS levels were higher in SMAD4-depleted cells than those in control cells within 2 to 6 hours after IR treatment (Fig. 4C and D; Supplementary Fig. S3B). The result indicates that induction of autophagy was accompanied by accumulation of ROS in SMAD4-depleted pancreatic cancer cells.

Figure 4.

SMAD4 depletion increased reactive oxygen species generation in PDAC cells. A and B, Panc-1 and MIA PaCa-2 cells were transfected with scrambled siRNA or SMAD4-specific siRNA for 48 hours and then treated with IR (6 Gy). SMAD4 depletion was confirmed by Western blot analysis. C and D, Cells were then incubated with ROS indicator (CM-H2DCFDA), and fluorescence intensity was assessed by flow cytometry at indicated time points. Labeled tert-butyl hydrogen peroxide (TBHP, 50 μmol/L) serve as a positive control. The differences in those two groups were detected using t test. *, P < 0.05; **, P < 0.01.

Figure 4.

SMAD4 depletion increased reactive oxygen species generation in PDAC cells. A and B, Panc-1 and MIA PaCa-2 cells were transfected with scrambled siRNA or SMAD4-specific siRNA for 48 hours and then treated with IR (6 Gy). SMAD4 depletion was confirmed by Western blot analysis. C and D, Cells were then incubated with ROS indicator (CM-H2DCFDA), and fluorescence intensity was assessed by flow cytometry at indicated time points. Labeled tert-butyl hydrogen peroxide (TBHP, 50 μmol/L) serve as a positive control. The differences in those two groups were detected using t test. *, P < 0.05; **, P < 0.01.

Close modal

Small molecule inhibitors of ROS and autophagy reverse SMAD4-depletion induced IR resistance

Because SMAD4 depletion caused higher level of autophagy and ROS production in pancreatic cancer cells, we set up experiments to test whether autophagy and ROS play a critical role on IR resistance induced by SMAD4 depletion in PDAC. We transfected Panc-1 cells with a control scramble siRNA or SMAD4-specific siRNA (Fig. 5A), and also treated cells with chloroquine (CQ), an autophagy inhibitor. These cells were subjected to increasing doses of IR treatment, and then seeded for colony formation. While only marginal difference was observed in the control Panc-1 cells with or without CQ treatment, cells transfected with SMAD4 siRNA were significantly more resistant to IR at 4 and 6 Gy doses compared with control cells, and CQ treatment partially reduced such resistance (Fig. 5B). In a separate experiment, Panc-1 cells transfected with a control or SMAD4-specific siRNA were treated with N-acetyl-l-cysteine (NAC), a ROS inhibitor, before IR. Similar to the result of CQ cotreatment, pretreatment with NAC re-sensitized cells to IR in SMAD4-depleted cells, but not in control cells (Fig. 5C). Similar phenomena were observed in the Panc-1 cells expressing SMAD4 shRNA after NAC and CQ treatment (Supplementary Fig. S4). Furthermore, we found that SMAD4-induced autophagy is partially rescued by ROS scavenger (Supplementary Fig. S5A) and NAC or CQ did not affect Rad 51 and Brca-1 protein levels (Supplementary Fig. S5B). Taken together, our data show that the autophagy and ROS inhibitors sensitized pancreatic cancer cells to IR, indicating that SMAD4 loss induced IR resistance is at least partially due to increased level of ROS and autophagy.

Figure 5.

SMAD4-induced IR-resistance is partially rescued by pretreatment of autophagy inhibitor or ROS scavenger. A, Panc-1 cells were transfected with scrambled siRNA or SMAD4-specific siRNA for 72 hours. SMAD4 depletion was confirmed by Western blot analysis. B and C, Cells were pretreated with 10 μmol/L CQ (B) or 3 mmol/L NAC (C) for 1 hour, and then treated with indicated doses of IR. Colony formation assays were conducted and more than 50 cells counted. Shown are the averages of triplicate samples. Standard errors are shown by error bars. The differences between the two groups selected to be compared were detected using repeated measures ANOVA. **, P < 0.01.

Figure 5.

SMAD4-induced IR-resistance is partially rescued by pretreatment of autophagy inhibitor or ROS scavenger. A, Panc-1 cells were transfected with scrambled siRNA or SMAD4-specific siRNA for 72 hours. SMAD4 depletion was confirmed by Western blot analysis. B and C, Cells were pretreated with 10 μmol/L CQ (B) or 3 mmol/L NAC (C) for 1 hour, and then treated with indicated doses of IR. Colony formation assays were conducted and more than 50 cells counted. Shown are the averages of triplicate samples. Standard errors are shown by error bars. The differences between the two groups selected to be compared were detected using repeated measures ANOVA. **, P < 0.01.

Close modal

Pancreatic tumors with SMAD4 depletion are resistant to radiotherapy in vivo

To validate whether the above cell-based findings were applicable in vivo, we generated orthotopic pancreatic cancer murine models by intra-pancreatic inoculation of Panc-1 cells, and treated tumor-bearing mice with IR (Fig. 6A). Although growth of the control Panc-1 tumors was significantly inhibited by IR treatment (P = 0.038), SMAD4 depletion largely abolished such radio-sensitivity of Panc-1 tumors (P = 0.819; Fig. 6B and C). Consistent with the cell-based results, SMAD4 depletion promoted basal LC3II and γ-H2AX expression in tumor tissues (Fig. 6D). We also found that γ-H2AX expression level was higher in tumor sections derived from SMAD4 shRNA-expressing cells than those from control shRNA cells. Similar to the cell-based study (Fig. 2), LC3-II and γ-H2AX expression levels were further increased after IR (Fig. 6D). These results suggest that SMAD4 is essential for pancreatic cancer radiosensitivity.

Figure 6.

SMAD4 depletion induced radio-resistance in an orthotopic pancreatic cancer mouse model. A, Schemes for the establishment and treatment of the pancreatic cancer orthotopic model. B and C, Nude mice were injected with 1 × 106 Panc-1 cells infected with control retroviral vector, or shSMAD4 vector with 5% Matrigel into the pancreas. After 21 days, tumors were irradiated thrice with 4-Gy dose of IR every other day. The mice were sacrificed at day 42, and the tumors were isolated, weighed, and compared between the groups using ANOVA. D, IHC was performed on serial sections using antibodies against SMAD4, LC3, and γ-H2AX in tumor tissues.

Figure 6.

SMAD4 depletion induced radio-resistance in an orthotopic pancreatic cancer mouse model. A, Schemes for the establishment and treatment of the pancreatic cancer orthotopic model. B and C, Nude mice were injected with 1 × 106 Panc-1 cells infected with control retroviral vector, or shSMAD4 vector with 5% Matrigel into the pancreas. After 21 days, tumors were irradiated thrice with 4-Gy dose of IR every other day. The mice were sacrificed at day 42, and the tumors were isolated, weighed, and compared between the groups using ANOVA. D, IHC was performed on serial sections using antibodies against SMAD4, LC3, and γ-H2AX in tumor tissues.

Close modal

Chemotherapy alone or chemotherapy combined with radiotherapy is used both after surgical resection (adjuvant therapy) and prior to the tumor resection (neoadjuvant therapy) of PDAC in North America (6–8). However, many patients with PDAC are either intrinsically resistant or develop acquired resistance to radiotherapy (44). It is crucial to understand the molecular mechanism of such radioresistance, so as, to develop effective targeted therapies for pancreatic cancer. In this study, we identified a critical role of SMAD4 in mediating pancreatic cancer cells' response to radiotherapy. Our in vitro and in vivo studies demonstrated that SMAD4 depletion led to radioresistance through induction of autophagy and ROS.

It was reported that 55% of PDAC showed SMAD4 inactivation (16, 17). Therefore, the SMAD4 status is considered to be a molecular biomarker for PDAC. However, how SMAD4 mutations contribute to the efficacy of radiotherapy of PDAC remains elusive. Homozygous deletion of SMAD4 gene or its inactivating mutation was observed in several types of cancer including pancreatic cancer (15) and colorectal cancer (45, 46). Multiple clinical studies showed that the PDAC patients with intact SMAD4 more commonly had local dominant pattern of tumor progression, whereas the patients with SMAD4 loss commonly had distant disease progression (17, 22–24). Recent research reported that the combination of Runx3 expression levels and SMAD4 status coordinately modulate the balance between dissemination and cell division in PDAC (47). However, very few studies have reported the correlation between SMAD4 and radioresistance in pancreatic cancer. Here we evaluated the effect of SMAD4 loss on the radioresistance of pancreatic cancer cells and in the animal model. We discovered that SMAD4 mutant cell lines were more resistant to IR than SMAD4 WT cell lines. SMAD4 depletion significantly increased IR resistance, and SMAD4 restoration significantly increased IR sensitivity of pancreatic cancer cells in vitro. Consistently, depletion of SMAD4 decreases the IR radiosensitivity of pancreatic tumor in vivo. Mechanistically, we found the SMAD4 depletion-induced IR resistance occurred via elevated levels of ROS and autophagy in pancreatic cancer cells. Pretreatment of autophagy inhibitor CQ or ROS scavenger NAC significantly increased radio-sensitivity of SMAD4-depleted pancreatic cancer cells.

Ionizing radiation generates large amount of intracellular free radicals and ROS (37, 38), and excessive production of ROS could induce autophagy (40, 41). Moderate autophagy, in turn, assists in the clearance of excessive ROS to protect cells from oxidative damage, which may reflect the balance of either cell survival or death (41, 43). There has been compelling evidence that clinically anticancer therapeutics, including DNA-damaging agents and IR, induce autophagy in cell culture and animal models (48, 49). Autophagy plays a cytoprotective role during anticancer therapy, and its inhibition can sensitize cancer cells to these therapies (31–33, 50). Activation of DDR may evoke autophagy as an early adaptive response, which can be considered as the DDR mechanisms of DNA damage tolerance. It is therefore expected that dysregulated autophagy may protect pancreatic cancer cells from IR-induced cellular damage, thereby enhancing radioresistance.

Indeed, we observed elevated level of autophagy in SMAD4-depleted pancreatic cancer cells after IR, and correlates with reduced radiosensitivity. Consistent with above reports, our results suggest that autophagy may function as a cytoprotective mechanism during radiotherapy in pancreatic cancer. Given that the process of autophagy may be used by cells to escape or delay apoptotic death in response to IR-induced DNA damage, molecules regulating autophagy and autophagic cell death may serve as viable targets for eliminating resistance to pancreatic cancer treatment.

Resistance to IR in pancreatic cancer has contributed to treatment challenges (9–13). Thus, understanding the molecular mechanisms underlying radioresistance is an important pursuit. In this study, we discovered SMAD4 loss-induced radioresistance, and elucidated the underlying mechanism, which may explain the phenomenon of which have been reported in previously clinical studies (23, 24). Our findings suggested that SMAD4 expression level correlated with radio-sensitivity of pancreatic cancer cells via regulating ROS and autophagy pathway. Thus, assessment of SMAD4 status may represent a vital screening test before radiotherapy. However, further clinical investigations are warranted to evaluate the relationship of SMAD4 status and survival advantages of chemoradiotherapy in patients with pancreatic cancer, which would be helpful to guide the administration of targeted therapies in the adjuvant setting based on SMAD4 status.

In conclusion, we have shown that SMAD4 depletion induced radioresistance in pancreatic cancer cells both in vitro and in vivo through elevated levels of ROS and autophagy under both basal and after IR treatment. However, the special mechanism by which SMAD4 participates into or regulates autophagy need to be confirmed on patient tumor tissues. Our investigation of the role of SMAD4 in regulating autophagy and radiosensitivity revealed a novel function for this frequently mutated gene in PDAC, which may have significant implication in deciding on the proper treatment plan for PDAC patients.

No potential conflicts of interest were disclosed.

Conception and design: F. Wang, X. Xia, C. Yang, E.J. Koay, H. Shen

Development of methodology: X. Xia, J. Mai, Y. Kang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): F. Wang, X. Xia, J. Shen, J. Mai, D. Kirui, J.B. Fleming, E.J. Koay

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): F. Wang, X. Xia, C. Yang

Writing, review, and/or revision of the manuscript: F. Wang, X. Xia, C. Yang, J. Shen, J.B. Fleming, E.J. Koay, H. Shen

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Yang, H.-C. Kim, D. Kirui

Study supervision: S. Mitra, M. Ferrari, H. Shen

The authors acknowledge financial support from the following sources: NIH grants (Nos. 1R01CA193880, U54CA143837, and U54CA210181), Department of Defense grants (No. W81XWH-12-1-0414), National Natural Science Foundation of China (No. 31771497, 81472578), and the Ernest Cockrell Jr. Presidential Distinguished Chair.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Kleeff
J
,
Korc
M
,
Apte
M
,
La Vecchia
C
,
Johnson
CD
,
Biankin
AV
, et al
Pancreatic cancer
.
Nat Rev Dis Primers
2016
;
2
:
16022
.
2.
Makohon-Moore
A
,
Iacobuzio-Donahue
CA
. 
Pancreatic cancer biology and genetics from an evolutionary perspective
.
Nat Rev Cancer
2016
;
16
:
553
65
.
3.
Siegel
RL
,
Miller
KD
,
Jemal
A
. 
Cancer statistics, 2016
.
CA Cancer J Clin
2016
;
66
:
7
30
.
4.
Kamisawa
T
,
Wood
LD
,
Itoi
T
,
Takaori
K
. 
Pancreatic cancer
.
Lancet
2016
;
388
:
73
85
.
5.
Neoptolemos
JP
. 
Adjuvant treatment of pancreatic cancer
.
Eur J Cancer
2011
;
47
Suppl 3
:
S378
80
.
6.
Tempero
MA
,
Arnoletti
JP
,
Behrman
SW
,
Ben-Josef
E
,
Benson
AB
 3rd
,
Casper
ES
, et al
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines
.
J Natl Compr Canc Netw
2012
;
10
:
703
13
.
7.
Loehrer
PJ
 Sr
,
Feng
Y
,
Cardenes
H
,
Wagner
L
,
Brell
JM
,
Cella
D
, et al
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial
.
J Clin Oncol
2011
;
29
:
4105
12
.
8.
Kooby
DA
,
Gillespie
TW
,
Liu
Y
,
Byrd-Sellers
J
,
Landry
J
,
Bian
J
, et al
Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base
.
Ann Surg Oncol
2013
;
20
:
3634
42
.
9.
Klinkenbijl
JH
,
Jeekel
J
,
Sahmoud
T
,
van Pel
R
,
Couvreur
ML
,
Veenhof
CH
, et al
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group
.
Ann Surg
1999
;
230
:
776
82
;
discussion 82–4
.
10.
Neoptolemos
JP
,
Dunn
JA
,
Stocken
DD
,
Almond
J
,
Link
K
,
Beger
H
, et al
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial
.
Lancet
2001
;
358
:
1576
85
.
11.
Neoptolemos
JP
,
Stocken
DD
,
Friess
H
,
Bassi
C
,
Dunn
JA
,
Hickey
H
, et al
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
.
N Engl J Med
2004
;
350
:
1200
10
.
12.
Adler
G
,
Seufferlein
T
,
Bischoff
SC
,
Brambs
HJ
,
Feuerbach
S
,
Grabenbauer
G
, et al
[Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies]
.
Dtsch Med Wochenschr
2007
;
132
:
1696
700
.
13.
Barhoumi
M
,
Mornex
F
,
Bonnetain
F
,
Rougier
P
,
Mariette
C
,
Bouche
O
, et al
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: definitive results of the 2000–2001 FFCD/SFRO phase III trial]
.
Cancer Radiother
2011
;
15
:
182
91
.
14.
Werner
J
,
Combs
SE
,
Springfeld
C
,
Hartwig
W
,
Hackert
T
,
Buchler
MW
. 
Advanced-stage pancreatic cancer: therapy options
.
Nat Rev Clin Oncol
2013
;
10
:
323
33
.
15.
Waddell
N
,
Pajic
M
,
Patch
AM
,
Chang
DK
,
Kassahn
KS
,
Bailey
P
, et al
Whole genomes redefine the mutational landscape of pancreatic cancer
.
Nature
2015
;
518
:
495
501
.
16.
Hahn
SA
,
Schutte
M
,
Hoque
AT
,
Moskaluk
CA
,
da Costa
LT
,
Rozenblum
E
, et al
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
.
Science
1996
;
271
:
350
3
.
17.
Blackford
A
,
Serrano
OK
,
Wolfgang
CL
,
Parmigiani
G
,
Jones
S
,
Zhang
X
, et al
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer
.
Clin Cancer Res
2009
;
15
:
4674
9
.
18.
Nikolic
A
,
Kojic
S
,
Knezevic
S
,
Krivokapic
Z
,
Ristanovic
M
,
Radojkovic
D
. 
Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: detection of two novel polymorphic nucleotide repeats
.
Cancer Epidemiol
2011
;
35
:
265
71
.
19.
Wang
LH
,
Kim
SH
,
Lee
JH
,
Choi
YL
,
Kim
YC
,
Park
TS
, et al
Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression
.
Clin Cancer Res
2007
;
13
:
102
10
.
20.
Bardeesy
N
,
Cheng
KH
,
Berger
JH
,
Chu
GC
,
Pahler
J
,
Olson
P
, et al
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
.
Genes Dev
2006
;
20
:
3130
46
.
21.
Izeradjene
K
,
Combs
C
,
Best
M
,
Gopinathan
A
,
Wagner
A
,
Grady
WM
, et al
Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas
.
Cancer Cell
2007
;
11
:
229
43
.
22.
Tascilar
M
,
Skinner
HG
,
Rosty
C
,
Sohn
T
,
Wilentz
RE
,
Offerhaus
GJ
, et al
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma
.
Clin Cancer Res
2001
;
7
:
4115
21
.
23.
Iacobuzio-Donahue
CA
,
Fu
B
,
Yachida
S
,
Luo
M
,
Abe
H
,
Henderson
CM
, et al
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
.
J Clin Oncol
2009
;
27
:
1806
13
.
24.
Crane
CH
,
Varadhachary
GR
,
Yordy
JS
,
Staerkel
GA
,
Javle
MM
,
Safran
H
, et al
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
.
J Clin Oncol
2011
;
29
:
3037
43
.
25.
Bornstein
S
,
White
R
,
Malkoski
S
,
Oka
M
,
Han
G
,
Cleaver
T
, et al
Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation
.
J Clin Invest
2009
;
119
:
3408
19
.
26.
Bhola
NE
,
Balko
JM
,
Dugger
TC
,
Kuba
MG
,
Sanchez
V
,
Sanders
M
, et al
TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer
.
J Clin Invest
2013
;
123
:
1348
58
.
27.
Papageorgis
P
,
Cheng
K
,
Ozturk
S
,
Gong
Y
,
Lambert
AW
,
Abdolmaleky
HM
, et al
Smad4 inactivation promotes malignancy and drug resistance of colon cancer
.
Cancer Res
2011
;
71
:
998
1008
.
28.
Kang
Y
,
Ling
J
,
Suzuki
R
,
Roife
D
,
Chopin-Laly
X
,
Truty
MJ
, et al
SMAD4 regulates cell motility through transcription of N-cadherin in human pancreatic ductal epithelium
.
PLoS One
2014
;
9
:
e107948
.
29.
Wang
F
,
Xu
L
,
Guo
C
,
Ke
A
,
Hu
G
,
Xu
X
, et al
Identification of RegIV as a novel GLI1 target gene in human pancreatic cancer
.
PLoS One
2011
;
6
:
e18434
.
30.
Valdiglesias
V
,
Giunta
S
,
Fenech
M
,
Neri
M
,
Bonassi
S
. 
gammaH2AX as a marker of DNA double strand breaks and genomic instability in human population studies
.
Mutat Res
2013
;
753
:
24
40
.
31.
Apel
A
,
Herr
I
,
Schwarz
H
,
Rodemann
HP
,
Mayer
A
. 
Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy
.
Cancer Res
2008
;
68
:
1485
94
.
32.
Rieber
M
,
Rieber
MS
. 
Sensitization to radiation-induced DNA damage accelerates loss of bcl-2 and increases apoptosis and autophagy
.
Cancer Biol Ther
2008
;
7
:
1561
6
.
33.
Amaravadi
RK
,
Yu
D
,
Lum
JJ
,
Bui
T
,
Christophorou
MA
,
Evan
GI
, et al
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
.
J Clin Invest
2007
;
117
:
326
36
.
34.
Kenzelmann Broz
D
,
Spano Mello
S
,
Bieging
KT
,
Jiang
D
,
Dusek
RL
,
Brady
CA
, et al
Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses
.
Genes Dev
2013
;
27
:
1016
31
.
35.
Wang
P
,
Zhang
J
,
Zhang
L
,
Zhu
Z
,
Fan
J
,
Chen
L
, et al
MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells
.
Gastroenterology
2013
;
145
:
1133
43
e12
.
36.
Tanida
I
. 
Autophagosome formation and molecular mechanism of autophagy
.
Antioxid Redox Signal
2011
;
14
:
2201
14
.
37.
Scherz-Shouval
R
,
Shvets
E
,
Fass
E
,
Shorer
H
,
Gil
L
,
Elazar
Z
. 
Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4
.
EMBO J
2007
;
26
:
1749
60
.
38.
Chen
Y
,
McMillan-Ward
E
,
Kong
J
,
Israels
SJ
,
Gibson
SB
. 
Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells
.
Cell Death Differ
2008
;
15
:
171
82
.
39.
Li
L
,
Chen
Y
,
Gibson
SB
. 
Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation
.
Cell Signal
2013
;
25
:
50
65
.
40.
Scherz-Shouval
R
,
Elazar
Z
. 
ROS, mitochondria and the regulation of autophagy
.
Trends Cell Biol
2007
;
17
:
422
7
.
41.
Scherz-Shouval
R
,
Elazar
Z
. 
Regulation of autophagy by ROS: physiology and pathology
.
Trends Biochem Sci
2011
;
36
:
30
8
.
42.
Tsugawa
H
,
Suzuki
H
,
Saya
H
,
Hatakeyama
M
,
Hirayama
T
,
Hirata
K
, et al
Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells
.
Cell Host Microbe
2012
;
12
:
764
77
.
43.
Filomeni
G
,
Desideri
E
,
Cardaci
S
,
Rotilio
G
,
Ciriolo
MR
. 
Under the ROS…thiol network is the principal suspect for autophagy commitment
.
Autophagy
2010
;
6
:
999
1005
.
44.
Yoneyama
H
,
Takizawa-Hashimoto
A
,
Takeuchi
O
,
Watanabe
Y
,
Atsuda
K
,
Asanuma
F
, et al
Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones
.
Anticancer Drugs
2015
;
26
:
90
100
.
45.
Yu
J
,
Wu
WK
,
Li
X
,
He
J
,
Li
XX
,
Ng
SS
, et al
Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer
.
Gut
2015
;
64
:
636
45
.
46.
Fleming
NI
,
Jorissen
RN
,
Mouradov
D
,
Christie
M
,
Sakthianandeswaren
A
,
Palmieri
M
, et al
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer
.
Cancer Res
2013
;
73
:
725
35
.
47.
Whittle
MC
,
Izeradjene
K
,
Rani
PG
,
Feng
L
,
Carlson
MA
,
DelGiorno
KE
, et al
RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma
.
Cell
2015
;
161
:
1345
60
.
48.
Kanzawa
T
,
Germano
IM
,
Komata
T
,
Ito
H
,
Kondo
Y
,
Kondo
S
. 
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
.
Cell Death Differ
2004
;
11
:
448
57
.
49.
Chen
JH
,
Zhang
P
,
Chen
WD
,
Li
DD
,
Wu
XQ
,
Deng
R
, et al
ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells
.
Autophagy
2015
;
11
:
239
52
.
50.
Gewirtz
DA
. 
The four faces of autophagy: implications for cancer therapy
.
Cancer Res
2014
;
74
:
647
51
.

Supplementary data